Helix Biopharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody from the Government of Canada

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that it has completed a licence agreement with the National Research Council of Canada (“NRC”) for the worldwide right to antiCEACAM6 antibody 2A3 for oncology applications.

The licence provides Helix the rights to use the antibody in multiple therapeutic modes including cell based therapy such as CAR-T, new DOS47 conjugates, standalone therapeutic and diagnostic applications on CEACAM6 bearing diseases. The antibody is protected by a US patent and other pending patent applications.